Revolution Medicines Inc. (RVMD) priced its initial public offering at $17 a share Wednesday evening, and will collect about $238 million. The clinical-stage oncology company said it would sell 14 million shares at that price, after increasing the size and target price of its offering ( ) Tuesday. Underwriters -- led by JPMorgan, Cowen, SVB Leerink and Guggenheim -- have access to an additional 2.1 million shares that could push the total higher. Revolution shares are expected to begin trading Thursday morning on the Nasdaq exchange under the ticker symbol RVMD.
-Jeremy C. Owens; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
February 12, 2020 19:56 ET (00:56 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.